THE PROBLEM OF STATIN USE IN PATIENTS WITH CARDIOVASCULAR DISEASES AND CONCOMITANT LIVER DISEASES. WHAT DO PRACTICING PHYSICIANS THINK ABOUT IT?
https://doi.org/10.20996/1819-6446-2015-11-2-167-169
Abstract
Aim. To study the opinion of doctors about the possibility of statins prescription to patients with cardiovascular diseases and concomitant chronic liver diseases.
Material and methods. Сross-sectional questioning of the random sample of physicians was performed. Results. 70 physicians (internists - 61.4%, cardiologists - 20.0%, neurologists - 5.7%, endocrinologists - 4.3%, and others) were interviewed. Work experience in the specialty of doctors was 25 years (14; 32.5). 22.9% of doctors completely exclude the possibility of statins prescription to patients with cardiovascular disease if they have concomitant liver disease. 70% of physicians consider it possible to use statin therapy in patients with liver disease, but only under certain conditions. Only a third of them, mostly internists, are ready to prescribe statins under condition of acceptable initial transaminase changes, and almost half of these doctors consider it possible to use statin therapy in patients with concomitant liver diseases only when serum transaminase levels are normal.
Conclusion. The physicians often and sometimes unreasonably find it impossible to use statin in patients with cardiovascular diseases and concomitant chronic liver diseases.
About the Authors
S. Yu. Martsevich
State Research Centre for Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
O. V. Lerman
State Research Centre for Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
N. P. Kutishenko
State Research Centre for Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
A. Yu. Suvorov
State Research Centre for Preventive Medicine
Russian Federation
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
References
1. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011: 32; 1769-818.
2. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol 2014;63(25 Pt B):2889-934.
3. Bhardwaj S.S., Chalasani N. Lipid lowering Agents That Cause Drug-Induced Hepatotoxicity. Clin Liver Dis 2007; 11(3): 597-614.
4. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97(Suppl): 52-60.
5. Alsheikh-Ali A.A., Maddukuri P.V., Han H., Karas R.H. Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer. Insights From Large Randomized Statin Trials. J Am CollCardiol 2007;50:409-18.
6. Macedo A.F., Taylor F.C., Casas J.F., et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMCMedicine 2014;12:51.
7. Onofrei M.D., Butler K.L., Fuke D.C., Miller H.B. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008;28(4):522–9.
8. Calderon R.M., Cubeddu L.X., Goldberg R.B., Schiff E.R. Statins in treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo ClinProc 2010; 85(4):349-56.
9. Cohen DE, Anania FA, Chalasani N; for the National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(8A):77C-81C.
10. McKenney J.M., Davidson M.H., Jacobson T.A., Guyton J.R. Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97(suppl):89–94.
11. Goodman SG, Langer A, Bastien NR, et al.; DYSIS Canadian Investigators. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol 2010;26(9):e330-5.
12. Argo CK, Loria P, Caldwell SH, Lorando A. Statins in disease: a molehill, an iceberg, or neither. Hepatology 2008; 48(2): 662-9.
13. Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaril coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. J ClinLipidol 2011; 5(6): 450-9.
14. Tikkanen MJ, Fayyad R, Faergeman O, et al.; IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013;168(4):3846-52.
Review
For citations:
Martsevich S.Yu., Lerman O.V., Kutishenko N.P., Suvorov A.Yu. THE PROBLEM OF STATIN USE IN PATIENTS WITH CARDIOVASCULAR DISEASES AND CONCOMITANT LIVER DISEASES. WHAT DO PRACTICING PHYSICIANS THINK ABOUT IT? Rational Pharmacotherapy in Cardiology. 2015;11(2):167-169. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-2-167-169
Views:
773
Email this article 